Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots
Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots
The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the Oxford/AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine.
What Happened: The EMA’s safety committee said that it considered all the available evidence around the instances of unusual blood clots with low blood platelets in people who received AstraZeneca’s shot. However, the agency confirms that the overall benefit-risk remains positive.
The EMA said most of the blood clot cases reported have occurred in women under 60 years of age within two weeks of their first vaccine dose. However, the specific risk factors have not yet been confirmed.
“A plausible explanation for these rare side events is an immune response to the vaccine similar to one seen in patients treated with heparin,” called heparin-induced thrombocytopenia, noted the agency.
The EMA said people who have received this vaccine should “seek medical assistance immediately” if they develop symptoms of this combination of blood clots and low blood platelets.
Why It Matters: In an interview with Italian newspaper Il Messaggero published Tuesday, Marco Cavaleri, chair of the EMA’s vaccine evaluation team, said: “In my opinion, we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction.”
Last month, EMA said that it had found the AZN shot safe and effective but added if a connection between the clots and the vaccine is established, the EMA will change its recommendations.
Today, Reuters reported that several European countries are looking at a mix of COVID-19 vaccine doses for people who have received the first dose of AstraZeneca shot amid the crisis.
Price Action: AZN shares dropped 0.4% at $49.03 during the market trading hours on the last check Wednesday.
The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the Oxford/AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine.
欧洲药品管理局(EMA)在经过深入分析后得出结论，不寻常的血液凝块应该被列为牛津大学的“非常罕见的副作用”。阿斯利康(AstraZeneca Plc)(纳斯达克股票代码：AZN)新冠肺炎疫苗。
What Happened: The EMA’s safety committee said that it considered all the available evidence around the instances of unusual blood clots with low blood platelets in people who received AstraZeneca’s shot. However, the agency confirms that the overall benefit-risk remains positive.
发生的事情：EMA的安全委员会表示，他们考虑了所有可获得的证据，证明接受阿斯利康注射的人出现了不寻常的血液凝块和低血小板。然而，该机构证实，总体收益-风险仍然是积极的。
The EMA said most of the blood clot cases reported have occurred in women under 60 years of age within two weeks of their first vaccine dose. However, the specific risk factors have not yet been confirmed.
EMA说，大多数报告的血栓病例都发生在60岁以下的女性，在她们接种第一剂疫苗后的两周内。不过，具体的风险因素尚未得到确认。
“A plausible explanation for these rare side events is an immune response to the vaccine similar to one seen in patients treated with heparin,” called heparin-induced thrombocytopenia, noted the agency.
该机构指出：“对于这些罕见的副作用，一个合理的解释是对疫苗的免疫反应，类似于肝素治疗的患者的免疫反应，称为肝素诱导的血小板减少症。”
The EMA said people who have received this vaccine should “seek medical assistance immediately” if they develop symptoms of this combination of blood clots and low blood platelets.
EMA说，接种过这种疫苗的人如果出现这种血栓和低血小板的组合症状，应该“立即寻求医疗帮助”。
Why It Matters: In an interview with Italian newspaper Il Messaggero published Tuesday, Marco Cavaleri, chair of the EMA’s vaccine evaluation team, said: “In my opinion, we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction.”
重要的原因：在周二发表的意大利报纸Il Messaggero的采访中，EMA疫苗评估小组主席马尔科·卡瓦拉利(Marco Cavalert I)表示：“在我看来，我们现在可以这么说，很明显，这与疫苗有关。不过，我们仍不清楚是什么原因导致了这种反应。“
Last month, EMA said that it had found the AZN shot safe and effective but added if a connection between the clots and the vaccine is established, the EMA will change its recommendations.
上个月，EMA表示，他们发现AZN疫苗是安全有效的，但补充说，如果凝块和疫苗之间建立了联系，EMA将改变其建议。
Today, Reuters reported that several European countries are looking at a mix of COVID-19 vaccine doses for people who have received the first dose of AstraZeneca shot amid the crisis.
今天，路透社报道，几个欧洲国家正在考虑为接种了第一剂新冠肺炎疫苗的人提供混合剂量的新冠肺炎疫苗。阿斯利康在危机中拍摄的。
Price Action: AZN shares dropped 0.4% at $49.03 during the market trading hours on the last check Wednesday.
价格行动：在周三的最后一次检查中，AZN股价在市场交易时段下跌0.4%，至49.03美元。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧